Agios-JPM-20240110.pdf

1、1J.P.Morgan Healthcare ConferenceAgios PharmaceuticalsBrian Goff,Chief Executive OfficerJanuary 10,20242Forward-looking statements This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Reform

2、Act of 1995.Such forward-looking statements include those regarding the potential benefits of PYRUKYND(mitapivat),AG-946,TMPRSS6 siRNA and its PAH stabilizer;Agios plans,strategies and expectations for its preclinical,clinical and commercial advancement of its drug development,including PYRUKYND,AG-

3、946 and its PAH stabilizer;Agios strategic vision and goals,including its key milestones for 2024 and potential catalysts through 2026;and the potential benefits of Agios strategic plans and focus.The words“anticipate,”“expect,”“goal,”“hope,”“milestone,”opportunity,“plan,”“potential,”“possible,”“str

4、ategy,”“will,”“vision,”and similar expressions are intended to identify forward-looking statements,although not all forward-looking statements contain these identifying words.Such statements are subject to numerous important factors,risks and uncertainties that may cause actual events or results to

5、differ materially from Agios current expectations and beliefs.For example,there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases,or that development of any of Agios product candidates will

6、successfully continue.There can be no guarantee that any positive developments in Agios business will result in stock price appreciation.Managements expectations and,therefore,any forward-looking statements in this presentation and various remarks we make during this presentation could also be affec